Heme oxygenase-1 inducer hemin prevents vascular thrombosis. 2007

Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
LABPART - EA 3852 - IFR135 - Université François Rabelais, Tours Cedex 1, France.

Hemin is a heme oxygenase-1 (HO-1) inducer which provides endogenous carbon monoxide known for playing roles in cell proliferation, inflammation or aggregation process. The objective of the current study was to examine the effect of prophylactic treatment with hemin in a thrombosis vascular model. Three groups of Wistar rats, control (n = 6), hemin (n = 6) and hemin + HO-1 inhibitor (n = 6), were used for this study. Hemin-treated animals received hemin (50 mg/kg/d; I.P.) for seven days and HO-1 inhibitor group received hemin at the same dose and SnPP IX (60 mg/kg/d; I.P.). All animals were exposed to electric stimulation of the left carotid according to Kawasaki's procedure to induce reproducible thrombus formation. The hemin treatment did not induce blood pressure disturbance. Effects of hemin on vascular thrombosis were quantified by histopathology and its influence on haemostasis was assessed by measuring prothrombin time (PT), activated partial thromboplastin time (APTT) and blood parameters at the end of treatment. The HO-1 mRNA and protein level variation were also checked out. Results showed that chronic treatment with hemin significantly (p < 0.01) reduced the vascular occlusion degree when compared to control and hemin SnPP groups with 7.2 +/- 4.6 vs. 71.1 +/- 14.7 and 74.0 +/- 8.8%, respectively. Moreover, we observed significant (p < 0.05) perturbations of blood parameters in hemin-treated and hemin-SnPP treated rats. Interestingly, hemin treatment did not significantly increase both PT and APTT. Finally, the HO-1 mRNA and protein levels were increased in hemin-treated carotid artery. In conclusion, hemin by inducing HO-1 expression may be a preventive agent against clinical disorders associated to an increased risk of thrombosis events and may limit haemorrhagic risks.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008665 Metalloporphyrins Porphyrins which are combined with a metal ion. The metal is bound equally to all four nitrogen atoms of the pyrrole rings. They possess characteristic absorption spectra which can be utilized for identification or quantitative estimation of porphyrins and porphyrin-bound compounds. Metalloporphyrin
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D011524 Protoporphyrins Porphyrins with four methyl, two vinyl, and two propionic acid side chains attached to the pyrrole rings. Protoporphyrin IX occurs in hemoglobin, myoglobin, and most of the cytochromes.
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002339 Carotid Arteries Either of the two principal arteries on both sides of the neck that supply blood to the head and neck; each divides into two branches, the internal carotid artery and the external carotid artery. Arteries, Carotid,Artery, Carotid,Carotid Artery
D002341 Carotid Artery Thrombosis Blood clot formation in any part of the CAROTID ARTERIES. This may produce CAROTID STENOSIS or occlusion of the vessel, leading to TRANSIENT ISCHEMIC ATTACK; CEREBRAL INFARCTION; or AMAUROSIS FUGAX. Thrombosis, Carotid Artery,Carotid Thrombosis,Common Carotid Artery Thrombosis,External Carotid Artery Thrombosis,Internal Carotid Artery Thrombosis,Thrombosis, Carotid,Thrombosis, Common Carotid Artery,Thrombosis, External Carotid Artery,Thrombosis, Internal Carotid Artery,Carotid Artery Thromboses

Related Publications

Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
October 2010, European journal of pharmacology,
Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
June 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
January 2004, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban,
Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
January 2009, Nephron. Experimental nephrology,
Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
May 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
April 2013, Life sciences,
Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
January 2016, Current trends in immunology,
Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
February 2008, Chinese medical journal,
Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
August 2001, Journal of cardiothoracic and vascular anesthesia,
Nicolas Desbuards, and Gaël Y Rochefort, and Deborah Schlecht, and Marie-Christine Machet, and Jean-Michel Halimi, and Véronique Eder, and Jean-Marc Hyvelin, and Daniel Antier
December 2017, Canadian journal of physiology and pharmacology,
Copied contents to your clipboard!